Abstract: The present invention provides a novel use of a compound having a plasminogen activator inhibitor-1 (PAI-1) inhibitory effect. Specifically, a compound having a PAI-1 inhibitory effect is used as an intranostimulator, an immune checkpoint inhibitor, an inhibitor for exacerbation of tumor cells caused by PD-L1, or an enhancer of immunotherapy for tumors, based on the inhibitory effect of the compound on expression induction of immune checkpoint molecules.

Abstract: According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.

Abstract: Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.

Abstract: According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.

Abstract: An autonomous distribution board receives feeding of power via a distribution board for a period during which grid power is supplied from a grid power source, while receiving power via an autonomous terminal of a power conversion apparatus for a period during which supplying of grid power from grid power source is stopped. Autonomous distribution board is connected with a specific load and the like. A measurement point switching apparatus is configured to select one from a current sensor configured to monitor a current that flows through a main breaker, and a current sensor configured to monitor a current that is supplied from power conversion apparatus to autonomous distribution board. A fuel battery is configured to adjust an output thereof based on an output of the selected one so that power by fuel battery is consumed by a general load, specific load and the like.

Abstract: Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.

Abstract: An autonomous distribution board receives feeding of power via a distribution board for a period during which grid power is supplied from a grid power source, while receiving power via an autonomous terminal of a power conversion apparatus for a period during which supplying of grid power from grid power source is stopped. Autonomous distribution board is connected with a specific load and the like. A measurement point switching apparatus is configured to select one from a current sensor configured to monitor a current that flows through a main breaker, and a current sensor configured to monitor a current that is supplied from power conversion apparatus to autonomous distribution board. A fuel battery is configured to adjust an output thereof based on an output of the selected one so that power by fuel battery is consumed by a general load, specific load and the like.

Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.

Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.

Abstract: Provided are intervertebral disk nucleus pulposus stem cells or progenitor cells that may be used for treatment of intervertebral disk disorders. An intervertebral disk nucleus pulposus cell is characterized by being isolated from the intervertebral disk nucleus pulposus of a vertebrate and is positive for at least one surface marker from among Tie2 and GD2. That is, the intervertebral disk nucleus pulposus stem cell is characterized by being at least Tie2-positive for the surface marker and) possesses a self-renewal ability as well as multipotency capable of differentiating into adipocytes, osteocytes, chondrocytes and neurons. Also provided is an intervertebral disk nucleus pulposus progenitor cell characterized by being at least Tie2-negative and GD2-positive for the surface marker and capable of differentiating into any of adipocytes, osteocytes, chondrocytes and neurons.

Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.

Abstract: A method for creating a monkey model of spinal cord injury, which includes exposing the dura mater of the cervical cord of a monkey and applying a load on the dura mater; the thus-created monkey model of spinal cord injury; and a method for evaluating a therapeutic drug for spinal cord injury by use of this model. According to the present invention, it is possible to create a monkey which is close to the human and thus useful as a model of human spinal cord injury. This model enables proper evaluation of therapeutic effects of various drugs on spinal cord injury. Through use of this model, it has been confirmed for the first time that transplantation therapy of human neural stem cells is efficacious against spinal cord injury.

Abstract: A nucleic acid-containing complex, containing a nucleic acid and a biodegradable polymer, especially a positively-charged water-insoluble biodegradable polymer, is disclosed. The complex has excellent properties of sustainedly releasing a desired nucleic acid, especially DNA, to a site in need of a treatment. Since the complex can be taken up to phagocytes such as macrophages and delivered specifically to the target site, the function of the nucleic acid can be exhibited in a target site specific manner, and thus more specific gene therapy can be achieved. The complex has no adverse effects, such as occurrence of recombinants or toxicity which could be caused by using a virus vector such as adenovirus, or liposome. Thus, the complex is particularly preferable for the field of gene therapy. Furthermore, the complex enhances the biological effect of the nucleic acid introduced into the cells, allowing a gene therapy with a lower dose of nucleic acids.

Abstract: The present invention provides a vacuum system including a vacuum pump capable of operating at a rotation rate controlled appropriately when a predetermined process is performed in a vacuum chamber, which contributes to energy conservation. The vacuum system serves as a semiconductor manufacturing system comprising a vacuum pump controller which has a gas flow mode and an auto-tuning mode for determining a rotation rate of a vacuum pump unit to set the rotation rate to a target value lower by a predetermined value than the full operation rate of gas flow rate control means under the condition that pressure within the process chamber is vacuum pressure necessary for the gas flow mode.

Abstract: The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).

Abstract: A nucleic acid-complex, containing a nucleic acid and a positively charged, water-insoluble biodegradable polymer, is disclosed. The complex has properties of sustainedly releasing a desired nucleic acid, especially DNA, to a site. The complex can be taken up by phagocytes such as macrophages and delivered to a target site, allowing the function of the nucleic acid to be exhibited in a target specific manner.

Abstract: Chimeric mice were constructed by transferring human CD34+ cells (hematopoietic stem cells) into a SCID mouse. In these chimeric mice, hematopoietic stem cells persistently differentiated into immune cells. Consequently, the chimeric mice can be immunized over a long time and enable one to obtain human antibodies against arbitrary antigens containing a human self-component.

Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.

Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.

Abstract: The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).